Each case of Central Line-Associated Bloodstream Infection (CLABSI) extends the patient’s hospital stay and incurs additional costs. The comprehensive physical, emotional, economic, and social impact on patients is significant, underscoring the critical need for improved CLABSI prevention strategies.
In 2024, CLABSI champions, in collaboration with the multidisciplinary CC CLABSI committee, spearheaded several initiatives, including:
Developing a staff/onboarding job aid for CLABSI based on current policy standards and practices.
Creating a job aid for blood culture collection in line with current policy standards and practices.
Integrating CLABSI and blood culture practices, education, and expectations into the onboarding process for all critical care staff and travelers.
Optimizing the CLABSI bundle audit tool and conducting regular audits.
Providing StatSeal staff education and training.
Conducting trials for Steripath and Cathgrip.
These efforts are aimed at enhancing patient outcomes and reducing the incidence of CLABSI, resulting in 95 days without a CLABSI in ICU; and 204 days without a CLABSI, as of December 31, 2024.